CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors
Jiawan Wang(Johns Hopkins University), Christine A. Pratilas(Johns Hopkins University)
Cited by 26
Related Papers
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
|Oncogene|2022|41
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors
|bioRxiv (Cold Spring Harbor Laboratory)|2023|5